{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:46:12Z","timestamp":1789850772920,"version":"4.0.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1097\/ftd.0000000000000557","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:03:57Z","timestamp":1532563437000},"page":"759-761","source":"Crossref","is-referenced-by-count":8,"title":["Documentation of a Little-Studied Designer Benzodiazepine After a Controlled Single Administration: II. Concentration Profile of Deschloroetizolam in Saliva"],"prefix":"10.1097","volume":"40","author":[{"given":"Alice","family":"Ameline","sequence":"first","affiliation":[{"name":"Institut de M\u00e9decine L\u00e9gale, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Arbouche","sequence":"additional","affiliation":[{"name":"Institut de M\u00e9decine L\u00e9gale, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S.","family":"Raul","sequence":"additional","affiliation":[{"name":"Institut de M\u00e9decine L\u00e9gale, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Kintz","sequence":"additional","affiliation":[{"name":"Institut de M\u00e9decine L\u00e9gale, Strasbourg, France"},{"name":"X-Petise Consulting, Oberhausbergen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","first-page":"5","article-title":"Les \u201cdesigner benzodiazepines\u201d: qu'en sait-on aujourd'hui?","volume":"30","author":"Chetraru","year":"2018","journal-title":"Toxicol Anal Clin."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/dta.2003","article-title":"Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays","volume":"9","author":"Pettersson Bergstrand","year":"2017","journal-title":"Drug Test Anal."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jchromb.2017.04.008","article-title":"Ultrasound-assisted low-density solvent dispersive liquid-liquid microextraction for the determination of 4-designer benzodiazepines in urine samples by gas chromatography-triple quadrupole mass spectrometer","volume":"1053","author":"Meng","year":"2017","journal-title":"J Chromatogr B."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/dta.2099","article-title":"Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism","volume":"9","author":"Kintz","year":"2016","journal-title":"Drug Test Anal."},{"key":"R5-20230814","first-page":"736","article-title":"Identifying metabolites of meclonazepam by high-resolution mass spectrometry using human liver microsomes, hepatocytes, a mouse model and authentic urine samples","volume":"19","author":"Vikingsson","year":"2017","journal-title":"Am Ass Pharm Sci."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/dta.2203","article-title":"Flubromazolam-Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine","volume":"10","author":"Huppertz","year":"2017","journal-title":"Drug Test Anal."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/jms.3279","article-title":"Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics","volume":"48","author":"Moosmann","year":"2013","journal-title":"J Mass Spectrom."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/jms.3840","article-title":"Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines\u2013an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam","volume":"51","author":"Moosmann","year":"2016","journal-title":"J Mass Spectrom."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201812000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:12:50Z","timestamp":1692051170000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201812000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000557","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}